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Abstract 
In addition to its AT1R (angiotensin receptor) blocking properties, telmisartan functions as a partial agonist at peroxisome 
proliferator-activated receptor-γ (PPARγ) which controls the expression of pro-inflammatory genes. We hypothesized that; in 
murine RAW 264.7 cell line, the anti-inflammatory effects of telmisartan may be mediated through PPARγ with NFκB 
deactivation. To test the hypothesis, the anti-inflammatory effect of telmisartan was assessed in lipopolysaccharide (LPS) 
intoxicated RAW 264.7 cells by MTT cytotoxicity assay. The protective effect was supported by the measuring transcription factor 
NFκB. The results indicate that telmisartan attenuated pro inflammatory mediator TNFα expression via NFκB deactivation and 
protected LPS intoxicated RAW 264.7 cell line. In conclusion the study indicates the existence of association between PPARγ and 
NFκB mediated inflammatory mechanism which was controlled by angiotensin receptor blocker telmisartan in RAW 264.7 cell line 
via NFκB deactivation effect.  
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1.  INTRODUCTION 
Angiotensin II (Ang II) type 1 receptor (AT1) stimulation 
results in hypertension, and AT1 blockers (ARBs) were used 
to treat high blood pressure. ARBs other beneficial effects 
include inflammatory and metabolic alterations [1]. Most of 
the ARBs are biphenyl-tetrazole derivatives with similar but 
not identical pharmacological profiles [2]. The biphenyl-
nontetrazole telmisartan is structurally unique and, in addition 
to its AT1 blocking properties, it functions as a partial agonist 
at peroxisome proliferator-activated receptor-γ (PPARγ) [3]. 
PPARγ full agonists reduce  
Pro-inflammatory gene expression [4] and metabolic 
alterations associated with cardiovascular disease [5]. Anti-
inflammatory effects of ARBs, were first established in the 
peripheral vasculature, later in the cerebral vasculature and in 
stress-induced gastric ulcerations [6]. These observations 
suggest that ARBs may exert anti-inflammatory effects 
beyond those associated with cardiovascular and metabolic 
disease. Candesartan reduced the peripheral and brain acute 
inflammation following systemic administration of the 
bacterial endotoxin lipopolysaccharide (LPS) [7], and in 
cultured circulating human monocytes expressing few AT1 
[8]. The PPARγ  activation in the brain suppresses the 
inflammatory response in neuronal cells, endothelial cells, 
astrocytes, microglia and also increases Aβ clearance [9] . It 
has been reported that rosiglitazone, a PPARγ  agonist, 
improves memory and learning in mice over expressed a 
mutant form of the human amyloid precursor protein [10] and 
suppresses cognitive function decline in early forms of AD. 
[11]. Telmisartan is also reported to improve memory 
impairment in mice that had been injected with Aβ. 
Therefore, telmisartan is expected to be an option for AD 
treatment. Macrophages play essential roles in inflammation 
and mobilization of the host defense against bacterial 
infection [12] and they release various inflammatory 
cytokines which regulate immune function. Further 
macrophages RAW 264.7 cell line that expresses TLR4 
receptor can be an ideal cell line to study the effect because, 
LPS can trigger excessive and uncontrolled production of 
inflammatory mediators, through TLR4 receptors,which can 
lead to potentially lethal systemic disorders such as septic 
shock. Hence in the present study the protective effect of 
telmisartan in LPS intoxicated RAW 264.7 cells was assessed 
through MTT cytotoxicity assay. To support the anti-
inflammatory effects of telmisartan, NFκB deactivation along 
with TNFα expression were measured. 
 
2.  METHODS AND MATERIALS 
2.1 Essential Chemicals and Reagents 
MTT (Sigma, USA), Minimum Essential Medium (MEM) 
(Invitrogen, USA), Fetal Bovine Serum (Invitrogen, USA), 
blueprint TM One Step RT-PCR Reaction kit (TAKARA, 
USA), PCR primers (Sigma, India), tissue culture grade 96 
well plates (Cornings, USA), PCR tubes and desired 
plastic wares (Tarsons, INDIA), PMSF, aprotinin, 
leupeptin, pepstatin (Sigma, USA) , ECL plus Western 
detection kit (Amersham Pharmacia Biotech, USA), 
Hybond-P   membranes  (Amersham   Pharmacia     
Biotech, Piscataway, NJ), antibody phospho- p65( Nfκβ)  
(Santa Cruz Biotech Inc, USA). 
2.2 Cell culture and LPS dose optimization by MTT assay 
RAW 264.7 cell line was obtained by National centre for cell 
science (NCCS) Pune, India. Cell lines were maintained in 
Minimum Essential Medium (MEM) supplemented with 10% 
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streptomycin (250µg/ml) and penicillin (250U/ml) in a 
carbon dioxide incubator at 5% CO2. About 2000 cells/well 
were added in 96 well tissue culture plates (Corning, USA) 
from well grown culture medium, the viability was tested 
using trypan blue dye with help of haemocytometer and 95% 
of viability was confirmed to carry the assay. The cells were 
then incubated with LPS at different doses (1 to 400µg/ml) 
for 24h. Then, the medium was changed again for all the 
groups and 10μl of MTT (5 mg/ml stock solution) was added 
and the plates were incubated for an additional 4h. The 
medium was discarded and the formazan blue, which was 
formed in the cells, was dissolved with 150μl of dimethyl 
sulfoxide (DMSO). The optical density was measured at 590 
nm. The toxicity and maximal inhibitory concentration 
(LD50) value was calculated using Graphpad Prism 4.03.       
2.3 Neuroprotective assessment by MTT assay 
The cells were incubated with LPS (LD50= 72µg/ml) and with 
telmisartan (1, 5 and 10µM) for 24h. The medium was 
changed after 24h and 10μl of MTT (5 mg/ml stock solution) 
was added, the plates were incubated for an additional 4h. 
The medium was discarded and the formazan blue insoluble 
crystal, which was formed in the cells, was dissolved with 
150μl of DMSO. The optical density was measured at 590nm. 
The protective effect of drug was evaluated using Graphpad 
Prism 4.03.  
2.4 Cell morphology observation   
About 10,000 cells were plated in six well plate (Corning, 
USA), incubated with LPS (72µg/ml) and telmisartan (1, 5 
and 10µM) for 24 h, the morphological changes in the RAW 
cells were observed by using phase contrast microscopy 
(Nikon, Japan). 
2.5 Preparation of cell lysates and Immunoblotting 
About 2×106 cells were plated in tissue culture grade petri 
plate (Corning, USA), incubated with LPS (72µg/ml) and 
telmisartan (1, 5 and 10µM) for 24h, the medium was 
separated and cells were washed with ice-cold phosphate 
buffer saline, scraped, and centrifuged at 5000 rpm for 5 min 
at 4
0C. The cell pellet was resuspended in 2000μl of lysis 
buffer (50mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium 
deoxycholate, 150mM NaCl, 1mM EGTA, 1mM PMSF, 
1mM aprotinin, 1mM leupeptin, 1mM pepstatin, 1mM 
sodium orthovanadate, and 1mM NaF) and incubated on ice 
for 30min. Cell lysates were obtained by centrifugation at 
12,000 rpm for 20min at 4
0C. The aliquot was separated. Cell 
lysates, medium and pellets were separated and stored at -
80
0C. Protein content in the cell lysates were estimated using 
Lowry’s method. Lysates from cells were separated by gel 
electrophoresis on 10% sodium dodecyl sulphate-
polyacrylamide   gels and transferred   to Hybond-P     
membranes (Amersham   Pharmacia   Biotech, Piscataway, 
NJ).  Membranes were then probed with antibody of anti 
phospho- p65( NFκB) and anti TNFα  (Santa Cruz Biotech 
Inc.) following the instructions provided  by the     
manufacturers. β- actin (Santa Cruz Biotech Inc.) was used 
for housekeeping gene expression control. Analysis was 
performed using the ECL plus Western detection kit 
(Amersham Pharmacia Biotech) and Gene Tools analysis 
software (Syngene, Cambridge, United Kingdom)  
 
3.  RESULTS 
3.1 The morphological changes in RAW 264.7 cell line 
with LPS treatment  
The untreated control cells were appeared cuboidal like shape 
with thin extensions. As the culture becomes denser, there 
may be another layer of rounded cells attached to the original 
monolayer. Morphological changes were observed in the cell 
lines incubated with 72µg/ml of LPS, compared to the 
untreated control group. LPS treated cells were bigger in size, 
irregular shape comparison to the control group. The 
morphology of the cells was restored with the treatment of 
telmisartan (5 and 10μm) in the presence of 72µg/ml of LPS. 
Figure: 1  
 
 
Figure 1:Phase contrast image of RAW 264.7 cell line at 
20X magnification.T10- Telmisartan 10μm; T5- Telmiartan 
5μm; T1- Telmisartan 1μm;LPS- LPS (72μg/ml) treated. 
Control- Untreated cells. 
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Figure 2:(A) LPS dose optimization in RAW 264.7 cell lines, Data are expressed as mean ± SEM. (n=9).  2(B) Telmisartan 
protective effect in RAW 264.7 cell line intoxicated with LD50  of LPS. C- Control cells; T10- Telmisartan 10μm; T5- 
Telmiartan 5μm; T1- Telmisartan 1μm; L- LPS (72μg/ml). (n=9). 
 
 
Figure 3: Telmisartan effect on P65( NFκB) activation in LPS intoxicated RAW 264.7 cell line by immune blotting. C- 
Control cells; T10- Telmisartan 10μm; T5- Telmiartan 5μm; T1- Telmisartan 1μm;L- LPS (72μg/ml) (a) Western blotting for 
p65 – Phospo-p65 Nfκβ,  β- Actin – Beta actin proteins in RAW 264.7 cell line.(b) Relative quantification for protein 
expression. Data are expressed as mean ± SEM (n=3). 
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Figure 4: Telmisartan effect on TNFα expression in LPS intoxicated RAW 264.7 cell line by immune blotting. C- Control 
cells; T10- Telmisartan 10μm; T5- Telmiartan 5μm; T1- Telmisartan 1μm;L- LPS (72μg/ml) (a) Western blotting for TNF – 
Phospo-p65 TNF, β- Actin – Beta actin proteins in RAW 264.7 cell line.(b) Relative quantification for protein expression. Data 
are expressed as mean ± SEM (n=3) 
 
3.2 Determination of LD50 of Lipopolysaccharide in RAW 
264.7 macrophage cell line in MTT assay 
LPS-induced cytotoxicity was expressed as cell viability and 
presented in Figure: 2A. The cell viability of normal control 
group was designated as 100%, indicating no cytotoxicity. 
LPS showed the decrease in cell viability in a dose dependent 
manner, indicating cytotoxicity.  The LD50 of LPS was found 
to be 72µg/ml. In the present study 72µg/ml was used as 
effective concentration of LPS to produce 50% cell death and 
inflammation in RAW cell lines and to test the protective 
mechanism of telmisartan. 
3.3 The protective effect of telmisartan in LD50 of LPS in 
RAW 264.7 macrophage cell line  
The protective effect of telmisartan against LPS cytotoxicity 
was presented in Figure: 2B. Telmisartan (1-10µM) showed 
protective effect in dose-dependent manner, cells treated with 
higher dose of telmisartan have shown maximum cell 
viability.  Telmisartan is non-toxic at the highest 
concentration studied (10µM), data were not presented. The 
percentage protection of the RAW cells with 10µM 
telmisartan treatment is approximately 40% compared to LPS 
treated group.  
3.4 Effect of telmisartan on NFκB activation in LPS 
intoxicated RAW 264.7 cell line 
The NFκB activation was significantly increased in the LPS 
treated cells in comparison to the controls and there was a 
75% increase in the activation of NFκB in LPS treated cells 
compared with control. Telmisartan attenuated the NFκB 
activation dose dependently. Telmisartan 10µM treatment 
decreased the activation of NFκB to 30% compared to LPS 
treated group. Figure: 3  
3.5 Effect of telmisartan on TNFα expression in LPS 
intoxicated RAW 264.7 cell line 
The TNFα expression was significantly increased in LPS 
treated cells compared to the control and there was an 80% 
increase in relative expression of TNFα in LPS treated cells 
in comparison to control. Telmisartan 1, 5, 10µM treatment 
attenuated the TNFα protein expression to 79%, 62%, and 
22% respectively in comparison to LPS treated cells.   
Figure: 4 
 
4.  DISCUSSION 
 In this study we demonstrated the telmisartan’s protection 
over the LPS induced inflammatory degeneration in RAW 
264.7 cell line through NFκB deactivation. Telmisartan 
significantly reduced the LPS induced inflammatory response 
through activation of PPARγ [13]. All ARBs inhibited LPS-
induced pro-inflammatory gene expression in THP-1 cells, 
which is consistent with the recent report of anti-
inflammatory effects of losartan through a PPARγ-dependent 
mechanism [14]. However studies suggest that telmisartan is 
capable of inducing the activation of PPARγ independently. 
Further, contrast report was also available stating that 
telmisartan, oxidase pathways in SK-N-SH neuronal cell line, 
and had no effect on NFκB activation associated with ERK 
and p38 MAPK [15]. This result suggests that telmisartan is 
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PPARγ activation in SK-N-SH cell line that expresses AT1R. 
So under these circumstances we should not totally exclude 
the participation of AT1R in the anti inflammatory effects of 
ARBs independent or associated with PPARγ activation.  
LPS activates NFκB via TLR4 receptors and stimulates 
various inflammatory mediators to induce the inflammatory 
mediated cytotoxicity. In our study LPS activated the NFκB 
transcriptional establishment and aggregated the TNFα pro 
inflammatory mediator protein expression and results in 50% 
decrease in cell viability. LPS stimulates various transcription 
factors essentially NFκB via MyD88 mediated activation of 
p38, ERK and JNK causes a chain of mechanism results in 
the production of pro inflammatory cytokine TNFα, IL1β, 
IL6 and inflammatory mediators iNOS, COX-2 etc [16].  In 
differentiated macrophages, angiotensin II promotes 
inflammation stimulation and mechanisms similar to the LPS 
induced inflammation mechanism. [17] Earlier candesartan 
attenuated angiotensin II mediated cell death in mesangial 
cells via LPS/TLR4 pathway [18]. NFκB is a main 
transcription factor that controls the expression of pro 
inflammatory cytokines and inflammatory mediators. 
Telmisartan attenuated the LPS mediated activation of NFκB 
in our demonstration. We interpreted in our study that the 
activation of p65 subunit, as a consequence of LPS induced 
NFκB activation, resulting in the elevation of pro 
inflammatory mediator TNF α. TNFα itself a potent 
inflammatory mediator that activates the various 
inflammatory cascades related to disease pathogenesis. TLR4 
activates predominantly NFkB, compared to AP1 and IRF3 
via MyD88 activation. [19]. Previously, telmisartan also 
reduced TNFα mRNA expression in the hippocampal region 
of rats with impaired spatial memory in Alzheimer’s in vivo 
model. Diminished TNF α production within the brain 
correlated with decreased local activation of microglia. 
Microglia are myeloid lineage CNS specific immune cells 
that are among the first responders to brain injury and 
function to secrete pro-inflammatory cytokines, enhance 
antigen presentation, destroy pathogens before they injure 
neurons, and clear dying cells [20]. Though several factors 
contribute to microglial stimulation, TNFα directly regulates 
activation. Mice lacking TNFα receptors showed decreased 
microglia activation and correspondingly higher levels of 
neuronal injury in the hippocampus after treatment with a 
dopaminergic neurotoxin [21, 22].  By our results and 
previous reports we strongly suggest that telmisartan 
protected over LPS intoxicated murine RAW 264.7 cell line 
by attenuating the NFκB activation thereby controlling the 
expression pro inflammatory mediator  TNFα and also we 
bear in mind that telmisartan a functional modulator of 
PPARγ. The link between PPARγ and NFκB mediated 
inflammatory mechanism need to be explored. 
5.  CONCLUSION 
Angiotensin II receptor type I (AT1) blocker telmisartan 
protected LPS intoxicated murine RAW 264.7 cell line by 
attenuating the NFκB activation thereby controlling the 
expression of pro inflammatory mediator TNFα, which might 
be an independent mechanism. Telmisartan a functional 
modulator of PPARγ hence, the link between PPARγ and 
NFκB mediated inflammatory mechanism need to be 
explored to further ascertain the telmisartan protective 
activity. 
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